Director Scott Garrett Sells 16,441 Shares of Hologic Inc (HOLX)
Director Scott Garrett has sold 16,441 shares of Hologic Inc (NASDAQ:HOLX) on March 14, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $75.5 per share, resulting in a total value of $1,241,295.5.
Hologic Inc is a medical technology company focused on women's health and well-being through early detection and treatment. The company's core business units are focused on diagnostics, breast health, gynecological surgery, and skeletal health.
Over the past year, the insider has sold a total of 36,441 shares of Hologic Inc and has not made any purchases of the stock. The recent sale by the insider is part of a trend observed over the past year, where there have been no insider buys and 10 insider sells.
On the day of the sale, Hologic Inc (NASDAQ:HOLX) shares were trading at $75.5, giving the company a market capitalization of $17.82 billion.
The company's price-earnings ratio stands at 35.98, which is above the industry median of 27.915 and also above the historical median price-earnings ratio for the company.
Hologic Inc's stock is currently trading with a price-to-GF-Value ratio of 1.23, indicating that the stock is considered Modestly Overvalued when compared to the GF Value of $61.45.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
